Literature DB >> 25487120

Bridging data models and terminologies to support adverse drug event reporting using EHR data.

G Declerck1, S Hussain, C Daniel, M Yuksel, G B Laleci, M Twagirumukiza, M-C Jaulent.   

Abstract

INTRODUCTION: This article is part of the Focus Theme of METHODs of Information in Medicine on "Managing Interoperability and Complexity in Health Systems".
BACKGROUND: SALUS project aims at building an interoperability platform and a dedicated toolkit to enable secondary use of electronic health records (EHR) data for post marketing drug surveillance. An important component of this toolkit is a drug-related adverse events (AE) reporting system designed to facilitate and accelerate the reporting process using automatic prepopulation mechanisms.
OBJECTIVE: To demonstrate SALUS approach for establishing syntactic and semantic interoperability for AE reporting.
METHOD: Standard (e.g. HL7 CDA-CCD) and proprietary EHR data models are mapped to the E2B(R2) data model via SALUS Common Information Model. Terminology mapping and terminology reasoning services are designed to ensure the automatic conversion of source EHR terminologies (e.g. ICD-9-CM, ICD-10, LOINC or SNOMED-CT) to the target terminology MedDRA which is expected in AE reporting forms. A validated set of terminology mappings is used to ensure the reliability of the reasoning mechanisms.
RESULTS: The percentage of data elements of a standard E2B report that can be completed automatically has been estimated for two pilot sites. In the best scenario (i.e. the available fields in the EHR have actually been filled), only 36% (pilot site 1) and 38% (pilot site 2) of E2B data elements remain to be filled manually. In addition, most of these data elements shall not be filled in each report.
CONCLUSION: SALUS platform's interoperability solutions enable partial automation of the AE reporting process, which could contribute to improve current spontaneous reporting practices and reduce under-reporting, which is currently one major obstacle in the process of acquisition of pharmacovigilance data.

Entities:  

Keywords:  EHR data models; Pharmacovigilance; adverse drug event reporting; secondary use of EHR; semantic interoperability

Mesh:

Year:  2014        PMID: 25487120     DOI: 10.3414/ME13-02-0025

Source DB:  PubMed          Journal:  Methods Inf Med        ISSN: 0026-1270            Impact factor:   2.176


  6 in total

1.  Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance.

Authors:  Suehyun Lee; Jongsoo Han; Rae Woong Park; Grace Juyun Kim; John Hoon Rim; Jooyoung Cho; Kye Hwa Lee; Jisan Lee; Sujeong Kim; Ju Han Kim
Journal:  Drug Saf       Date:  2019-05       Impact factor: 5.606

2.  Clinical Informatics Researcher's Desiderata for the Data Content of the Next Generation Electronic Health Record.

Authors:  Timothy I Kennell; James H Willig; James J Cimino
Journal:  Appl Clin Inform       Date:  2017-12-21       Impact factor: 2.342

3.  Ontology-based Vaccine and Drug Adverse Event Representation and Theory-guided Systematic Causal Network Analysis toward Integrative Pharmacovigilance Research.

Authors:  Yongqun He
Journal:  Curr Pharmacol Rep       Date:  2016-03-11

4.  Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks.

Authors:  Vassilis G Koutkias; Marie-Christine Jaulent
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

5.  Towards achieving semantic interoperability of clinical study data with FHIR.

Authors:  Hugo Leroux; Alejandro Metke-Jimenez; Michael J Lawley
Journal:  J Biomed Semantics       Date:  2017-09-19

6.  Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk.

Authors:  Mark R Davies; Michael Martinec; Robert Walls; Roman Schwarz; Gary R Mirams; Ken Wang; Guido Steiner; Andy Surinach; Carlos Flores; Thierry Lavé; Thomas Singer; Liudmila Polonchuk
Journal:  Cell Rep Med       Date:  2020-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.